Mass spectrometry identified 11 citrullination modification residues in PAD-treated rhGK (Supplementary Fig. 3 and all citrullinated peptides identified in PAD-treated rhGK are listed in supplementary Table 6). This evidence concerns the gene RHCG and peripheral arterial disease.